Day: January 3, 2025

ZUG, Switzerland, Jan. 04, 2025 (GLOBE NEWSWIRE) — Attached is a Notification of Major Changes in Voting Rights, in relation to Brunnur vaxtarsjóður slhf‘s distribution of its shares in Oculis Holding AG to Brunnur Vaxtarsjóður slhf‘s shareholders.AttachmentNotification of Major Changes in Voting Rights – Brunnur

Greenville, South Carolina , Jan. 03, 2025 (GLOBE NEWSWIRE) — ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) reports that it has now completed the sale of its 68% share ownership interest in Achieve Behavioral Health Greenville LLC, (“Achieve”) as originally announced December 30, 2024. In exchange for its ownership interest in Achieve, the Company received cash of US$360,000, plus the settlement of US$120,000 in amounts owing between ARCpoint and the buyers of the Achieve interest, for total consideration of US$480,000. The Transaction was a Non-Arm’s Length Transaction in accordance with the policies of the TSXV. The Transaction also constituted a “related party transaction” within the meaning of Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101”). Notwithstanding...

Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) — Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it had made an equity grant to a new employee under its 2021 Inducement Plan, as amended. The Company approved the issuance of an option to purchase 2,600 shares of the Company’s common stock to a new employee, as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The option was issued on January 3, 2025, and has an exercise price equivalent to the closing price of the Company’s common stock on the date of grant. The option vests in equal proportions on a quarterly basis over...

TORONTO, Jan. 03, 2025 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announces that it has granted a total of 800,000 stock options to two of the three directors of the Company at an exercise price of $0.22 per share. The stock options vest immediately on the grant date and have a five-year term, expiring January 2, 2030. The Chairman and CEO, Fabio Chianelli, did not receive stock options. About PharmaTher Holdings Ltd. PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is focused on the development and commercialization of KETARX™ (Ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, neurological, and medical countermeasures indications. Learn more at PharmaTher.com. For more information...

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company’s board of directors has approved the consolidation (the “Consolidation”) of the Company’s issued and outstanding common shares (the “Common Shares”) on the basis of one (1) post-Consolidation Common Share for every fifteen (15) pre-Consolidation Common Shares. The Consolidation is being implemented to ensure that the Company continues to comply with the listing requirements of The Nasdaq Capital Market (the “Nasdaq”). The Consolidation is subject to approval by the Toronto Stock Exchange (the “TSX”) and is expected to become effective...

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company’s Annual General Meeting of Shareholders (the “Meeting”), which was originally scheduled to be held on Thursday, January 23, 2025, has been rescheduled. The Meeting is now scheduled to be held on Wednesday, February 5, 2025, at 9:00 a.m. (ET) at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. The record date for the Meeting, December 9, 2024, is unchanged and applies to the postponed Meeting. The Meeting has been postponed due to delays stemming from the disruption in postal service in Canada, and to provide further time to...

Turin, 3rd January 2025. Iveco Group N.V. (EXM: IVG) announces that effective immediately Thomas Hilse, President, Firefighting Business Unit of Iveco Group and CEO of Magirus GmbH, has chosen to leave the company to pursue other opportunities. He has served in his responsibilities from 2021 until now, also ensuring in the last period continuity in the transition of Magirus GmbH to Mutares SE & Co. KGaA (ISIN: DE000A2NB650), which was subject of a separate announcement made earlier today. Olof Persson, CEO, Iveco Group, said: “I want to thank Thomas for his passion, hard work and leadership. He joined IVECO in 2019 as the Brand President and has been a key member of the Iveco Group Senior Leadership Team since its foundation in 2022. Thomas led the Firefighting business and the launch of the new MAGIRUS fire truck portfolio...

Nokia CorporationStock Exchange Release3 January 2025 at 22:30 EET Nokia Corporation: Repurchase of own shares on 03.01.2025 Espoo, Finland – On 3 January 2025 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows:Trading venue (MIC Code) Number of shares Weighted average price / share, EUR*XHEL 872,093 4.31CEUX – –BATE – –AQEU – –TQEX – –Total 872,093 4.31* Rounded to two decimals On 22 November 2024, Nokia announced that its Board of Directors is initiating a share buyback program to offset the dilutive effect of new Nokia shares issued to the shareholders of Infinera Corporation and certain Infinera Corporation share-based incentives. The repurchases in compliance with the...

Quanzhou, China, Jan. 03, 2025 (GLOBE NEWSWIRE) — INLIF LIMITED (Nasdaq: INLF) (the “Company” or “INLIF”), a company engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms, today announced the closing of its initial public offering (the “Offering”) of 2,000,000 ordinary shares at a public offering price of US$4.00 per ordinary share. The ordinary shares began trading on the Nasdaq Capital Market on January 2, 2025 under the ticker symbol “INLF.” The Company received aggregate gross proceeds of US$8 million from the Offering, before deducting underwriting discounts and other related expenses payable by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 300,000 ordinary shares at the public offering price,...